# US 2021/0172019 A1 · Method for screening a subject for cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0172019 A1
- Document ID: US20210172019A1
- Status: Published application
- Kind: A1
- Application number: 16/770,351
- Filed: 2018-12-06
- Published: 2021-06-10
- Earliest claimed: 2017-12-07
- Assignees: Inserm (Institut National De La Sante Et De La Recherche Medicale); Universite De Montpellier; Institut Regional Du Cancer De Montpellier
- Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale); Université de Montpellier; Institut Régional du Cancer de Montpellier
- Inventors: Alain THIERRY; Cynthia SANCHEZ
- Web page: https://patentgrep.com/patent/US20210172019A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to the diagnostic of cancerous subject. Indeed, the inventors observed by using a Q-PCR based methods and sequencing methods that quantification of specific single stranded DNA fragments obtained from cell free nucleic acids (cfDNA) may discriminate cfDNA from healthy and cancer derived subjects. Single stranded DNA fragments obtained from CfDNA or specific range of single stranded DNA fragments are rather lower or higher when derived from healthy subject than from cancer subject. More, specific ratios for different size or range of single stranded DNA fragments varies between cancer subjects and healthy individuals. These values are sufficiently and significantly different to be used as values to determine whether a human subject may have cancer or not as a screening test. Thus, the invention relates to a method for screening a subject for a cancer comprising the steps of extracting and denaturing cfDNA, determining the single strand fragment level upon their size distribution, and calculate these former values to screen an individual for cancer.

## Claims

### Claim 1

A method for screening a subject for cancer comprising the steps of:
i) extracting cell free nucleic acids (cfDNA) from a sample obtained from the subject; and
a)
ii) denaturating the cell free nucleic acids (cf DNA) to obtain single stranded DNA fragments;
iii) determining a level of at least one single stranded DNA fragment having a length between 20 to 400 nucleotides;
iv) comparing the level determined at step iii) with a predetermined reference value; and
v) concluding that the subject suffers from cancer when the level determined at step iii) differs from the predetermined reference value; and/or
b)
vi) determining a level of a first single stranded DNA fragment having a length between 20 to 400 nucleotides;
vii) determining a level of a second single stranded DNA fragment having a length between 20 to 400 nucleotides;
viii) calculating a ratio of the level determined at step vi) to the level determined at step vii) or a ratio of the level determined at step vii) to the level determined at step vi);
ix) comparing the ratio determined at step viii) with a predetermined corresponding reference value; and
x) concluding that the subject suffers from cancer when the ratio determined at step viii) differs from the predetermined corresponding reference value.

### Claim 2

(canceled)

### Claim 3

A method for screening a subject for a cancer comprising the steps of:
i) extracting the cell free nucleic acids from a sample obtained from the subject;
ii) denaturating the cell free nucleic acids to obtain single stranded DNA fragments;
iii) determining the level of a group of single stranded DNA fragments having a length ranging from 20 to 400 nucleotides; and
a)
iv) comparing the level determined at step iii) with a predetermined reference value and;
v) concluding that the subject suffers from a cancer when the level determined at step iii) differs from the predetermined reference value; and/or
b)
vi) determining the level of one single stranded DNA fragment having a length of from 20 to 400 nucleotides;
vii) calculating a ratio of the level determined at step iii) to the level determined at step vi) and/or a ratio of the level determined at step iv) to the level determined at step iii);
viii) comparing the at least one ratio determined at step vii) with a predetermined corresponding reference value, and;
ix) concluding that the subject suffers from a cancer when the at least one ratio determined at step vii) differs from the predetermined corresponding reference value.

### Claim at position 4

4-5. (canceled)

### Claim 6 (depends on 1)

The method according to claim 1, wherein the single stranded DNA fragment has a length of 20; 21; 22; 23; 24; 25; 26; 27; 28; 29; 30; 31; 32; 33; 34; 35; 36; 37; 38; 39; 40; 41; 42; 43; 44; 45; 46; 47; 48; 49; 50; 51; 52; 53; 54; 55; 56; 57; 58; 59; 60; 61; 62; 63; 64; 65; 66; 67; 68; 69; 70; 71; 72; 73; 74; 75; 76; 77; 78; 79; 80; 81; 82; 83; 84; 85; 86; 87; 88; 89; 90; 91; 92; 93; 94; 95; 96; 97; 98; 99; 100; 101; 102; 103; 104; 105; 106; 107; 108; 109; 110; 111; 112; 113; 114; 115; 116; 117; 118; 119; 120; 121; 122; 123; 124; 125; 126; 127; 128; 129; 130; 131; 132; 133; 134; 135; 136; 137; 138; 139; 140; 141; 142; 143; 144; 145, 146; 147; 148; 149; 150; 151; 152; 153; 154; 155; 156; 157; 158; 159; 160; 161; 162; 163; 164; 165; 166; 167; 168; 169; 170; 171; 172; 173; 174; 175; 176; 177; 178; 179; 180; 181; 182; 183; 184; 185; 186; 187; 188; 189; 190; 191; 192; 193; 194; 195; 196; 197; 198; 199; 200; 201; 202; 203; 204; 205; 206; 207; 208; 209; 210; 211; 212; 213; 214; 215; 216; 217; 218; 219; 220; 221; 222; 223; 224; 225; 226; 227; 228; 229; 230; 231; 232; 233; 234; 235; 236; 237; 238; 239; 240; 241; 242; 243; 244; 245; 246; 247; 248, 249; 250; 251; 252; 253; 256; 257; 258; 259; 260; 261; 262; 263; 264; 265; 266; 267; 268; 269; 270; 271; 272; 273; 274; 275; 276; 277; 278; 279; 280; 281; 282; 283; 284; 285; 286; 287; 288; 289; 290; 291; 292; 293; 294; 295; 296; 297; 298; 299; 300; 301; 302; 303; 304; 305; 306; 307; 308; 309; 310; 311; 312; 313; 314; 315; 316; 317; 318; 319; 320; 321; 322; 323; 324; 325; 326; 327; 328; 329; 330; 331; 332; 333; 334; 335; 336; 337; 338; 339; 340; 341; 342; 343; 344; 345; 346; 347; 348; 349; 350; 351; 352; 353; 354; 355; 356; 357; 358; 359; 360; 361; 362; 363; 364; 365; 366; 367; 368; 369; 370; 371; 372; 373; 374; 375; 376; 377; 378; 379; 380; 381; 382; 383; 384; 385; 386; 387; 388; 389; 390; 391; 392; 393; 394; 395; 396; 397; 398; 399 or 400 nucleotides.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the sample is blood, ascite, urine, amniotic fluid, feces, saliva or cerebrospinal fluids.

### Claim at position 7

8-9. (canceled)

### Claim 10

A method of treating cancer in subject in need thereof, comprising
i) extracting cell free nucleic acids (cfDNA) from a sample obtained from the subject;
ii) denaturating the cell free nucleic acids (cf DNA) to obtain single stranded DNA fragments;
iii) determining a level of at least one single stranded DNA fragment having a length between 20 to 400 nucleotides;
iv) comparing the level determined at step iii) with a predetermined reference value; and
v) administering one or more cancer treatments to the subject when the level determined at step iii) differs from the predetermined reference value, wherein the one or more cancer treatments include radiotherapy, chemotherapy, and immunotherapy; or
b)
vi) determining a level of at least one first single stranded DNA fragment having a length between 20 to 400 nucleotides;
vii) determining a level of at least one second single stranded DNA fragment having a length between 20 to 400 nucleotides;
viii) calculating a ratio of the level determined at step vi) to the level determined at step vii) or a ratio of the level determined at step vii) to the level determined at step vi);
ix) comparing the ratio determined at step viii) with a predetermined corresponding reference value; and
x) administering one or more cancer treatments to the subject when the ratio determined at step iii) differs from the predetermined reference value, wherein the one or more cancer treatments include radiotherapy, chemotherapy, and immunotherapy.
